{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:04:07Z","timestamp":1790841847012,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T00:00:00Z","timestamp":1505692800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1038\/nm.4399","type":"journal-article","created":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T15:19:58Z","timestamp":1505747998000},"page":"1234-1240","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":516,"title":["Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells"],"prefix":"10.1038","volume":"23","author":[{"given":"Elodie M","family":"Kuntz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Baquero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M","family":"Michie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Tardito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa L","family":"Holyoake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G Vignir","family":"Helgason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9770-0956","authenticated-orcid":false,"given":"Eyal","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,18]]},"reference":[{"key":"BFnm4399_CR1","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker, B.J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408\u20132417 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnm4399_CR2","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood.V99.1.319","volume":"99","author":"SM Graham","year":"2002","unstructured":"Graham, S.M. et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99, 319\u2013325 (2002).","journal-title":"Blood"},{"key":"BFnm4399_CR3","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2011","unstructured":"Corbin, A.S. et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J. Clin. Invest. 121, 396\u2013409 (2011).","journal-title":"J. Clin. Invest."},{"key":"BFnm4399_CR4","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","volume":"119","author":"A Hamilton","year":"2012","unstructured":"Hamilton, A. et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 119, 1501\u20131510 (2012).","journal-title":"Blood"},{"key":"BFnm4399_CR5","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/imr.12234","volume":"263","author":"TL Holyoake","year":"2015","unstructured":"Holyoake, T.L. & Helgason, G.V. Do we need more drugs for chronic myeloid leukemia? Immunol. Rev. 263, 106\u2013123 (2015).","journal-title":"Immunol. Rev."},{"key":"BFnm4399_CR6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nature18288","volume":"534","author":"SA Abraham","year":"2016","unstructured":"Abraham, S.A. et al. Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. Nature 534, 341\u2013346 (2016).","journal-title":"Nature"},{"key":"BFnm4399_CR7","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nrc2817","volume":"10","author":"DA Tennant","year":"2010","unstructured":"Tennant, D.A., Dur\u00e1n, R.V. & Gottlieb, E. Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer 10, 267\u2013277 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnm4399_CR8","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley, J.D. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243, 290\u2013293 (1973).","journal-title":"Nature"},{"key":"BFnm4399_CR9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","volume":"36","author":"J Groffen","year":"1984","unstructured":"Groffen, J. et al. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36, 93\u201399 (1984).","journal-title":"Cell"},{"key":"BFnm4399_CR10","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/0092-8674(84)90438-0","volume":"37","author":"JB Konopka","year":"1984","unstructured":"Konopka, J.B., Watanabe, S.M. & Witte, O.N. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 37, 1035\u20131042 (1984).","journal-title":"Cell"},{"key":"BFnm4399_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","volume":"109","author":"P Rousselot","year":"2007","unstructured":"Rousselot, P. et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109, 58\u201360 (2007).","journal-title":"Blood"},{"key":"BFnm4399_CR12","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon, F.X. et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 11, 1029\u20131035 (2010).","journal-title":"Lancet Oncol."},{"key":"BFnm4399_CR13","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross, D.M. et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122, 515\u2013522 (2013).","journal-title":"Blood"},{"key":"BFnm4399_CR14","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.stem.2010.07.011","volume":"7","author":"T Simsek","year":"2010","unstructured":"Simsek, T. et al. The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche. Cell Stem Cell 7, 380\u2013390 (2010).","journal-title":"Cell Stem Cell"},{"key":"BFnm4399_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.stem.2012.10.011","volume":"12","author":"K Takubo","year":"2013","unstructured":"Takubo, K. et al. Regulation of glycolysis by Pdk functions as a metabolic checkpoint for cell cycle quiescence in hematopoietic stem cells. Cell Stem Cell 12, 49\u201361 (2013).","journal-title":"Cell Stem Cell"},{"key":"BFnm4399_CR16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.stem.2012.11.022","volume":"12","author":"WM Yu","year":"2013","unstructured":"Yu, W.M. et al. Metabolic regulation by the mitochondrial phosphatase PTPMT1 is required for hematopoietic stem cell differentiation. Cell Stem Cell 12, 62\u201374 (2013).","journal-title":"Cell Stem Cell"},{"key":"BFnm4399_CR17","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.2882","volume":"18","author":"K Ito","year":"2012","unstructured":"Ito, K. et al. A PML\u2013PPAR-\u03b4 pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. Nat. Med. 18, 1350\u20131358 (2012).","journal-title":"Nat. Med."},{"key":"BFnm4399_CR18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrc3483","volume":"13","author":"A Carracedo","year":"2013","unstructured":"Carracedo, A., Cantley, L.C. & Pandolfi, P.P. Cancer metabolism: fatty acid oxidation in the limelight. Nat. Rev. Cancer 13, 227\u2013232 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnm4399_CR19","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.cell.2015.07.017","volume":"162","author":"LB Sullivan","year":"2015","unstructured":"Sullivan, L.B. et al. Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells. Cell 162, 552\u2013563 (2015).","journal-title":"Cell"},{"key":"BFnm4399_CR20","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2015.07.016","volume":"162","author":"K Birsoy","year":"2015","unstructured":"Birsoy, K. et al. An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis. Cell 162, 540\u2013551 (2015).","journal-title":"Cell"},{"key":"BFnm4399_CR21","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/ncb3233","volume":"17","author":"S Cardaci","year":"2015","unstructured":"Cardaci, S. et al. Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis. Nat. Cell Biol. 17, 1317\u20131326 (2015).","journal-title":"Nat. Cell Biol."},{"key":"BFnm4399_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/cdd.2016.116","volume":"24","author":"E Norberg","year":"2017","unstructured":"Norberg, E. et al. Differential contribution of the mitochondrial translation pathway to the survival of diffuse large B-cell lymphoma subsets. Cell Death Differ. 24, 251\u2013262 (2017).","journal-title":"Cell Death Differ."},{"key":"BFnm4399_CR23","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.ccr.2011.10.015","volume":"20","author":"M Skrti\u0107","year":"2011","unstructured":"Skrti\u0107, M. et al. Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell 20, 674\u2013688 (2011).","journal-title":"Cancer Cell"},{"key":"BFnm4399_CR24","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/bs.mie.2015.05.016","volume":"561","author":"GM Mackay","year":"2015","unstructured":"Mackay, G.M., Zheng, L., van den Broek, N.J. & Gottlieb, E. Analysis of cell metabolism using LC\u2013MS and isotope tracers. Methods Enzymol. 561, 171\u2013196 (2015).","journal-title":"Methods Enzymol."},{"key":"BFnm4399_CR25","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1080\/15548627.2016.1162359","volume":"12","author":"M Karvela","year":"2016","unstructured":"Karvela, M. et al. ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells. Autophagy 12, 936\u2013948 (2016).","journal-title":"Autophagy"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nm.4399.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm.4399","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/nm.4399","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/nm.4399.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T23:03:46Z","timestamp":1684451026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm.4399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,18]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["BFnm4399"],"URL":"https:\/\/doi.org\/10.1038\/nm.4399","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,18]]},"assertion":[{"value":"20 December 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.G. is a founder and shareholder of MetaboMed, Ltd. T.L.H. has previously received research support from Bristol-Myers Squibb and Novartis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}